• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·US·Healthcare·VNRX
Share

VolitionRx Limited Stocks

$ 1.33Last Updated 11.06.2026

Issuer Rating

2/7
Performance

Modest

Risk

High

Recommendation

Sell

Market Cap

$ 7.27M

$ 1.33
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Very low or no dividends

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Latest news

26.02.2026 16:07

Cancer blood test maker VolitionRX soars 25% in a day on reported commercial progress

05.12.2025 16:20

Epigenetics co. VolitionRx climbs 10% on sepsis assay news, still offers 730% upside

18.04.2025 12:00

VolitionRx, maker of cancer blood test, could have upside of 500%

27.03.2025 15:43

Direct offering weighs on blood-based cancer test maker VolitionRx

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

VolitionRx Limited is an international epigenetics firm that specializes in pioneering advanced blood tests. These diagnostics are developed to aid in the global detection of various cancers and other diseases. Their innovative product suite includes Nu.Q, engineered for cancer detection; Nu.Q Nets, which monitors immune system health; Nu.Q Vet, a cancer screening solution tailored for animal applications; Nu.Q Capture, designed to enhance diagnostic precision by concentrating samples; and Nu.Q Discover, a specialized platform for nucleosome profiling. The cornerstone of their blood test technology is their proprietary Nucleosomics platform. The company maintains its headquarters in Austin, Texas.

Company Valuation

Overvalued
2/7

Considering past and projected metrics, the stock is 'expensive' compared to its peers.

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

11.06.2026 22:46

Trump canceled planned new strikes on Iran. Oil below $90 per barrel

11.06.2026 22:30

Wall Street assessed the potential of SpaceX stock: optimists expect a 40% increase from the IPO price

11.06.2026 21:39

Bezos' AI startup has increased its valuation to $41 billion, what do we know about it?

11.06.2026 20:51

Retail investors are willing to buy back more than $70 billion worth of SpaceX stock - Bloomberg

11.06.2026 20:19

Emirates has come up with a way to bring tourists back to Dubai. What does it offer?

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn
  • X (Twitter)
  • LinkedIn
Oninvest© 2026